ERS Genomics and genOway Enter CRISPR/Cas9 Agreement
Dublin, Ireland and Lyon, France, 07 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned…
Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent
Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third Arguments filed in opposition to JP6692856 rejected JP2019-210828 represents third Japanese patent  Dublin,…
ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement
ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement License agreement to enhance GenScript’s CRISPR offering for gene and cell therapy research Dublin, Ireland…
ERS Genomics and NUVISAN ICB sign CRISPR/Cas9 license agreement
CRISPR offerings to enhance NUVISAN’s drug development service portfolio Dublin, Ireland and Berlin, Germany, 19 April 2021: ERS Genomics Limited, which was formed to provide…
ERS Genomics and Setsuro Tech sign CRISPR/Cas9 license agreement
DUBLIN, Ireland & Tokushima, Japan, 10 March 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Setsuro Tech, a biotechnology start-up using genome-editing techniques to develop and supply cell and animal models, today announced a non-exclusive license agreement granting Setsuro Tech access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan.
ERS Genomics licenses CRISPR gene editing technology to Otsuka Pharmaceutical
DUBLIN, Ireland, 3 March 2021: ERS Genomics Limited, which was formed to provide broad access to foundational CRISPR/Cas9 intellectual property today announced the signing of a license agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka). The license grants Otsuka access to CRISPR/Cas9 genome editing technology for its internal research and development initiatives to address areas of unmet medical need.
ERS Genomics expands team with appointment of Jon Kratochvil as VP Business Development
DUBLIN, Ireland, 01 March 2021: ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced the appointment of Jon Kratochvil as Vice-President for Business Development & Licensing for North America.
ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement
Dublin, Ireland and Seoul, Korea,23 February 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and G+FLAS Life Sciences, Inc. (G+FLAS), a biotechnology company developing research tools and reagents associated with CRISPR technology, today announced a non-exclusive license agreement granting G+FLAS access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
ERS Genomics and ZeClinics sign CRISPR/Cas9 license agreement
DUBLIN, Ireland & Barcelona, Spain,16 February 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and ZeClinics, a contract research organization using zebrafish to carry out services focused on analyzing the safety, efficacy and biomedical relevance of new compounds, today announced a non-exclusive license agreement granting ZeClinics access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
All articles loaded
No more articles to load